Anti-double stranded DNA antibodies: A rational diagnostic approach in limited-resource settings

Admou, Brahim; Eddehbi, F.E.; Elmoumou, Lahcen; Elmojadili, Saad; Salami, Abdelmouïne; Oujidi, Mohammed; Brahim, Imane; Hazime, Raja

doi:10.1016/j.plabm.2022.e00285

Cited by 4 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 18 In fact, comparison of the characteristics of CLIFT-positive and CLIFT-negative patients (with or without SLE) (comparison A, table 2 ) revealed that positive CLIFT results were associated with higher dsDNA FEIA values and the homogeneous pattern, as previously described. 19 Highly significant differences were also detected for the remaining variables, except for sex. Similarly, a comparison of the variables between the four groups showed the same pattern (comparison E, table 2 ).…”

Section: Discussionmentioning

confidence: 89%

“…In the CLIFT negative group, 81 patients did not meet the EULAR 2019 criteria for SLE, 11 patients met the EULAR 2019 criteria and were diagnosed during the study period, and 47 patients fulfilled the EULAR 2019 criteria having been previously diagnosed and were under treatment (figure 2). Mean age was 49 years (SD 19), and most patients were women (n=188, 84.7%). The median ANA titre was 1/320 (IQR 1/160-1/640).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Longitudinal study of patients with discrepant results in CLIFT and a solid-phase dsDNA antibody assay: does a gold standard dsDNA assay exist?

Trujillo Aguilera,

Bernardo Serrano,

Navas

et al. 2023

Lupus Sci Med

View full text Add to dashboard Cite

ObjectiveAntidouble-stranded DNA (dsDNA) antibodies are essential for diagnosis and follow-up of systemic lupus erythematous (SLE). To ensure the best diagnostic approach, most healthcare laboratories opt for a combination of highly sensitive methods, such as solid-phase immunoassays, and highly specific methods, such as theCrithidia luciliaeindirect immunofluorescence test (CLIFT). Even so, discordant results are common, thus hindering the diagnostic process. Therefore, this study aimed to characterise a cohort of patients with discrepant results for a dsDNA fluorescence enzyme immunoassay (FEIA) and CLIFT during 2016–2018 and to follow patients up until December 2021.MethodsWe performed an observational, longitudinal and retrospective study on 417 samples from 257 patients who had been referred for suspected connective tissue diseases or followed up after diagnosis. All of them were positive for antinuclear antibodies (ANAs) using an indirect immunofluorescence assay (IFA) on Hep-2 cells, the entry criterion in our laboratory, and positive for FEIA dsDNA. Samples were then tested with CLIFT according to our routine protocol, which includes CLIFT testing after FEIA dsDNA results ≥10 UI/ml. After the assessment of data quality, the final analysis was based on 222 patients.ResultsEighty-three patients (37.4%) had positive results in both tests and met the diagnostic criteria for SLE. However, 139 patients (62.6%) had discrepant results (FEIA+, CLIFT–). Of these, 58 patients (41.7%) had a diagnosis of SLE, with 47 (33.8%) having been previously diagnosed and under treatment. The remaining 11 patients (7.9%) had a new diagnosis of SLE, which was made up within 4 years of the initial screening. A total of 81 of the 139 patients (57.5%) with discrepant results did not meet lupus criteria during the follow-up period.ConclusionsThe study showed that CLIFT could be negative in both treated and newly diagnosed SLE, thus underlining the importance of follow-up of dsDNA-positive results using solid-phase tests. Therefore, quantitative tests such as FEIA could add value to the diagnosis and management of patients with suspected SLE.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Resultsmentioning

confidence: 99%

Longitudinal study of patients with discrepant results in CLIFT and a solid-phase dsDNA antibody assay: does a gold standard dsDNA assay exist?

Trujillo Aguilera,

Bernardo Serrano,

Navas

et al. 2023

Lupus Sci Med

View full text Add to dashboard Cite

show abstract

“…The exploration of CTS-EVs in systemic lupus erythematosus (SLE) reveals a unique molecular signature indicative of the underlying immune dysregulation. These EVs carry specific biomarkers, including antinuclear antibodies (ANAs), anti-double-stranded DNA antibodies (anti-dsDNA), and anti-Smith antibodies, pinpointing cellular targets within SLE [ 179 ]. Additionally, cytokines carried by CTS-EVs, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), contribute to the inflammatory environment associated with SLE [ 180 ].…”

Section: Cts-evs In Physiology and Pathologymentioning

confidence: 99%

“…Focusing on biomarkers from implicated cell types, such as B cells and dendritic cells, offers a targeted understanding of SLE pathogenesis. Leveraging these specific biomarkers holds promise for precise diagnostic assays and informs potential therapeutic strategies aimed at modulating the identified molecular pathways contributing to immune dysregulation in SLE [ 179 , 180 ].…”

Section: Cts-evs In Physiology and Pathologymentioning

confidence: 99%

Cell Type-Specific Extracellular Vesicles and Their Impact on Health and Disease

Amin,

Massoumi,

Tewari

et al. 2024

IJMS

View full text Add to dashboard Cite

Extracellular vesicles (EVs), a diverse group of cell-derived exocytosed particles, are pivotal in mediating intercellular communication due to their ability to selectively transfer biomolecules to specific cell types. EVs, composed of proteins, nucleic acids, and lipids, are taken up by cells to affect a variety of signaling cascades. Research in the field has primarily focused on stem cell-derived EVs, with a particular focus on mesenchymal stem cells, for their potential therapeutic benefits. Recently, tissue-specific EVs or cell type-specific extracellular vesicles (CTS-EVs), have garnered attention for their unique biogenesis and molecular composition because they enable highly targeted cell-specific communication. Various studies have outlined the roles that CTS-EVs play in the signaling for physiological function and the maintenance of homeostasis, including immune modulation, tissue regeneration, and organ development. These properties are also exploited for disease propagation, such as in cancer, neurological disorders, infectious diseases, autoimmune conditions, and more. The insights gained from analyzing CTS-EVs in different biological roles not only enhance our understanding of intercellular signaling and disease pathogenesis but also open new avenues for innovative diagnostic biomarkers and therapeutic targets for a wide spectrum of medical conditions. This review comprehensively outlines the current understanding of CTS-EV origins, function within normal physiology, and implications in diseased states.

show abstract

Diagnosis of Skin Diseases

Prohic

2024

Dermatovenerology Textbook

View full text Add to dashboard Cite

Anti-double stranded DNA antibodies: A rational diagnostic approach in limited-resource settings

Cited by 4 publications

References 36 publications

Longitudinal study of patients with discrepant results in CLIFT and a solid-phase dsDNA antibody assay: does a gold standard dsDNA assay exist?

Longitudinal study of patients with discrepant results in CLIFT and a solid-phase dsDNA antibody assay: does a gold standard dsDNA assay exist?

Cell Type-Specific Extracellular Vesicles and Their Impact on Health and Disease

Diagnosis of Skin Diseases

Contact Info

Product

Resources

About